Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 3.

Moesges, R., Kasche, E. M., Raskopf, E., Singh, J., Sohlich, L., Astvatsatourov, A., Shah-Hosseini, K., Pirotton, S., Haazen, L., Durham, S. R., Legon, T., Zadoyan, G. and Shamji, M. H. (2018). A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy. Allergy, 73 (4). S. 896 - 905. HOBOKEN: WILEY. ISSN 1398-9995

Shamji, M. H., Kasche, E. M., Zadoyan, G., Astvatsourov, A., Durham, S. R., Pirotton, S., Legon, T. and Moesges, R. (2015). Hydrolyzed Lolium perenne peptide fragments administered subcutaneously to hay fever patients induce allergen-specific IgG(4) and blocking antibodies after two or more weeks of treatment. Allergy, 70. S. 631 - 633. HOBOKEN: WILEY-BLACKWELL. ISSN 1398-9995

Zadoyan, G., V, Allekotte, S., Shamji, M. H., Kasche, E. M., Singh, J., Astvatsatourov, A., Shah-Hosseini, K., Pirotton, S., Legon, T., Caplanusi, A., Durham, S. R. and Mosges, R. (2016). Immunological biomarker predict clinical effects in subcutaneous peptide allergen immunotherapy. Allergy, 71. S. 319 - 321. HOBOKEN: WILEY-BLACKWELL. ISSN 1398-9995

This list was generated on Thu Mar 28 16:33:50 2024 CET.